Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

Ítems similars

• Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors
  per: Nathan, Bavithra, et al.
  Publicat: (2013)
• Cytochrome P450 3A Inhibition by Atazanavir and Ritonavir, but Not Demography or Drug Formulation, Influences Saquinavir Population Pharmacokinetics in Human Immunodeficiency Virus Type 1-Infected Adults
  per: von Hentig, Nils, et al.
  Publicat: (2009)
• Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
  per: Xu, Lianhong, et al.
  Publicat: (2010)
• Exercise therapy for human immunodeficiency virus/AIDS patients: Guidelines for clinical exercise therapists
  per: Grace, Jeanne M., et al.
  Publicat: (2015)
• Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen
  per: von Hentig, Nils, et al.
  Publicat: (2008)